BioStock: CombiGene’s CEO on the favourable position

After the agreement with Spark Therapeutics in October 2021, CombiGene is in a particularly favourable position – this much is clear in this year’s Q3 report. The stock exchange responded by trading up the share by 12 per cent. BioStock contacted CEO Jan Nilsson to get his comment on the report.

Read the full article about CombiGene at biostock.se:

https://www.biostock.se/en/2022/11/combigenes-ceo-on-the-favourable-position/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/